Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5114923 | SCIOS LLC | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
May, 2014
(9 years ago) |
Natrecor is owned by Scios Llc.
Natrecor contains Nesiritide.
Natrecor has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Natrecor are:
Natrecor was authorised for market use on 10 August, 2001.
Natrecor is available in for solution;intravenous dosage forms.
Natrecor can be used as method to induce natriuresis, diuresis and/or vasodilation.
The generics of Natrecor are possible to be released after 19 May, 2014.
Drugs and Companies using NESIRITIDE ingredient
Market Authorisation Date: 10 August, 2001
Treatment: Method to induce natriuresis, diuresis and/or vasodilation
Dosage: FOR SOLUTION;INTRAVENOUS